公开(公告)号：US20170281671A1

公开(公告)日：2017-10-05

申请号：US15627332

申请日：2017-06-19

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： Michael Dockal ,  Fritz Scheiflinger ,  Sabine Knappe ,  Susanne Till ,  Ton Hai ,  Paul Sanders

IPC分类号： A61K31/795 ,  A61K31/7024 ,  A61K31/37 ,  A61K31/727 ,  A61K38/37 ,  A61K38/48

CPC分类号： A61K31/795 ,  A61K31/37 ,  A61K31/7024 ,  A61K31/727 ,  A61K38/37 ,  A61K38/4846 ,  A61K2300/00

摘要： The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

公开(公告)号：US20170360823A1

公开(公告)日：2017-12-21

申请号：US15696111

申请日：2017-09-05

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： Michael Dockal ,  Fritz Scheiflinger ,  Sabine Knappe ,  Susanne Till ,  Ton Hai ,  Paul Sanders ,  Prasad Dande ,  Cong Jiang

IPC分类号： A61K31/737 ,  C07H5/10 ,  A61K45/06 ,  C08B37/16 ,  A61K31/715

CPC分类号： A61K31/737 ,  A61K31/715 ,  A61K45/06 ,  C07H5/10 ,  C08B37/0012 ,  A61K2300/00

摘要： The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

公开(公告)号：US20200215099A1

公开(公告)日：2020-07-09

申请号：US16819770

申请日：2020-03-16

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： Michael Dockal ,  Fritz Scheiflinger ,  Sabine Knappe ,  Susanne Till ,  Ton Hai ,  Paul Sanders ,  Prasad Dande ,  Cong Jiang

IPC分类号： A61K31/737 ,  A61K31/724 ,  A61P7/02 ,  C08B37/16 ,  C07H5/10 ,  A61K45/06 ,  A61K31/715

摘要： The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

公开(公告)号：US20190125782A1

公开(公告)日：2019-05-02

申请号：US16224665

申请日：2018-12-18

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： Michael Dockal ,  Fritz Scheiflinger ,  Sabine Knappe ,  Susanne Till ,  Ton Hai ,  Paul Sanders ,  Prasad Dande ,  Cong Jiang

IPC分类号： A61K31/737 ,  A61K31/715 ,  C07H5/10 ,  C08B37/16 ,  A61K45/06

摘要： The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

公开(公告)号：US20190381092A1

公开(公告)日：2019-12-19

申请号：US16457450

申请日：2019-06-28

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： Michael Dockal ,  Fritz Scheiflinger ,  Sabine Knappe ,  Susanne Till ,  Ton Hai ,  Paul Sanders

IPC分类号： A61K31/795 ,  A61K9/00 ,  A61P7/04

摘要： The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

公开(公告)号：US20180256634A1

公开(公告)日：2018-09-13

申请号：US15977956

申请日：2018-05-11

申请人： Baxalta Incorporated ,  Baxalta GmbH

发明人： Michael Dockal ,  Fritz Scheiflinger ,  Sabine Knappe ,  Susanne Till ,  Ton Hai ,  Paul Sanders ,  Prasad Dande ,  Cong Jiang

IPC分类号： A61K31/737 ,  C08B37/16 ,  A61K45/06 ,  C07H5/10 ,  A61K31/715

CPC分类号： A61K31/737 ,  A61K31/715 ,  A61K45/06 ,  C07H5/10 ,  C08B37/0012 ,  A61K2300/00

摘要： The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.